Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung ...

Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...

In a recent study published in The Lancet Regional Health-Southeast Asia, researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung ...

The relation between body mass index, comorbidity, choice of surgery, and prognostic factors in early breast cancer: Data from a nation-wide Danish cohort No significant financial relationships to ...

Companies will provide classification information on EGFR mutations in non-small cell lung cancer that may guide clinical decision-making In a retrospective analysis, the MD Anderson EGFR ...